What is Small Pharma?
Small Pharma Inc. operates at the intersection of biotechnology and mental health, focusing on the development of short-acting psychedelics designed to address treatment-resistant conditions. The company's primary asset, SPL026, is currently undergoing Phase IIa clinical trials for depressive disorder, representing a significant advancement in neuro-pharmacology. Beyond its lead candidate, the firm maintains a robust preclinical portfolio, including tryptamine analogues such as SPL028 and SPL029, as well as an oral formulation of 6-hydroxynorketamine, known as SPL801. Headquartered in London, the company is strategically positioned to leverage the UK's vibrant life sciences ecosystem to drive its therapeutic innovations forward.
How much funding has Small Pharma raised?
Small Pharma has raised a total of $1.8M across 3 funding rounds:
Multiple Rounds
$1.8M
Private Equity (2017): $1M with participation from Angel CoFund
Grant (2017): $174K led by Angel CoFund
Other Financing Round (2017): $584K supported by Innovate UK
Key Investors in Small Pharma
Angel CoFund
Angel CoFund is a 100M GBP investment fund dedicated to supporting promising UK businesses through angel and co-investment. The fund collaborates with sector-focused angel investors to align interests and enhance the investment process.
Innovate UK
Innovate UK is a government-backed innovation agency that provides grants and support to high-potential businesses to foster technological advancement and economic growth.
What's next for Small Pharma?
With the recent influx of capital, Small Pharma is poised to advance its clinical trial infrastructure and expand its research capabilities. The strategic focus will likely remain on the successful progression of SPL026 through Phase IIa, while simultaneously de-risking the preclinical pipeline. As the company matures, the emphasis will shift toward establishing long-term efficacy data and preparing for potential regulatory pathways that could bring these novel treatments to market. Investors will be closely monitoring the firm's ability to translate its scientific research into scalable, patient-centric therapeutic solutions, which remains the primary driver of its long-term valuation and market impact.
See full Small Pharma company page
